319 related articles for article (PubMed ID: 18579417)
1. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells.
Liu SF; Wang H; Lin XC; Xiang H; Deng XY; Li W; Tang M; Cao Y
Cell Biol Int; 2008 Aug; 32(8):1006-13. PubMed ID: 18579417
[TBL] [Abstract][Full Text] [Related]
2. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells.
Liu SF; Wang H; Li ZJ; Deng XY; Xiang H; Tao YG; Li W; Tang M; Cao Y
Eur J Pharmacol; 2008 Jul; 589(1-3):8-13. PubMed ID: 18571159
[TBL] [Abstract][Full Text] [Related]
3. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.
Chia MC; Leung A; Krushel T; Alajez NM; Lo KW; Busson P; Klamut HJ; Bastianutto C; Liu FF
Clin Cancer Res; 2008 Feb; 14(4):984-94. PubMed ID: 18281530
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
6. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Feng WH; Kenney SC
Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192
[TBL] [Abstract][Full Text] [Related]
8. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
9. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
Ho CH; Chen CL; Li WY; Chen CJ
Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Feng WH; Israel B; Raab-Traub N; Busson P; Kenney SC
Cancer Res; 2002 Mar; 62(6):1920-6. PubMed ID: 11912175
[TBL] [Abstract][Full Text] [Related]
11. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of NF‑κB inhibitors in combination with anti‑herpes agents on Epstein‑Barr virus‑positive gastric carcinoma in vitro.
Ordonez P; Nandakumar A; Koriyama C; Yamomoto M; Akiba S
Mol Med Rep; 2016 Sep; 14(3):2359-67. PubMed ID: 27430429
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.
Wang L; Shan L; Lo KW; Yin J; Zhang Y; Sun R; Zhong J
J Gene Med; 2008 Oct; 10(10):1124-33. PubMed ID: 18642396
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of NF-kappaB inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines.
Berger N; Ben Bassat H; Klein BY; Laskov R
Exp Hematol; 2007 Oct; 35(10):1495-509. PubMed ID: 17889719
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
16. Cell-cycle regulators, bcl-2 and NF-kappaB in Epstein-Barr virus-positive gastric carcinomas.
Chang MS; Lee HS; Jung EJ; Kim CW; Lee BL; Kim WH
Int J Oncol; 2005 Nov; 27(5):1265-72. PubMed ID: 16211221
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of Epstein-Barr virus-encoded small RNAs (EBERs) in nasopharyngeal carcinoma.
Yoshizaki T; Endo K; Ren Q; Wakisaka N; Murono S; Kondo S; Sato H; Furukawa M
Auris Nasus Larynx; 2007 Mar; 34(1):73-8. PubMed ID: 17129696
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappa B inhibition reduces markedly cell proliferation in Epstein-Barr virus-infected stomach cancer, but affects variably in Epstein-Barr virus-negative stomach cancer.
Jeong JY; Woo JH; Kim YS; Choi S; Lee SO; Kil SR; Kim CW; Lee BL; Kim WH; Nam BH; Chang MS
Cancer Invest; 2010 Feb; 28(2):113-9. PubMed ID: 19968495
[TBL] [Abstract][Full Text] [Related]
19. HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer.
Lifang Y; Min T; Midan A; Ya C
J Exp Clin Cancer Res; 2008 Sep; 27(1):42. PubMed ID: 18811956
[TBL] [Abstract][Full Text] [Related]
20. A nuclear factor-kappaB inhibitor BAY11-7082 inhibits interactions between human endothelial cells, T cells, and monocytes.
Zhu B; Liu Z; Wang P; Wu C; Xu H
Transplant Proc; 2008 Oct; 40(8):2724-8. PubMed ID: 18929846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
